The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Xilio Therapeutics Inc shares valued at $6,841 were sold by Frankenfield Christopher James on Jan 02 ’25. At $0.98 per share, Frankenfield Christopher James sold 6,954 shares. The insider’s holdings dropped to 12,421 shares worth approximately $8446.28 following the completion of this transaction.
Also, Brennan Kevin M. sold 1,803 shares, netting a total of over 1,774 in proceeds. Following the sale of shares at $0.98 each, the insider now holds 3,197 shares.
Before that, GILEAD SCIENCES, INC. had added 1,759,978 shares to its account. In a trade valued at $1,830,377, the 10% Owner bought Xilio Therapeutics Inc shares for $1.04 each. Upon closing the transaction, the insider’s holdings increased to 1,759,978 shares, worth approximately $6.19 million.
As published in their initiating research note from Chardan Capital Markets on December 21, 2022, Xilio Therapeutics Inc [XLO] has been a Buy and the price target has been revised to $7. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in early January. As of November 16, 2021, Raymond James has initiated its “an Outperform” rating for XLO. Earlier on November 16, 2021, Morgan Stanley initiated its rating. Their recommendation was “an Overweight” for XLO stock.
Analyzing XLO Stock Performance
On last trading session,, Xilio Therapeutics Inc [NASDAQ: XLO] plunged -1.36% to $0.68. The stock’s lowest price that day was $0.6672, but it reached a high of $0.6904 in the same session. During the last five days, there has been a surge of approximately 0.78%. Over the course of the year, Xilio Therapeutics Inc shares have dropped approximately -28.42%.
Support And Resistance Levels for Xilio Therapeutics Inc (XLO)
RSI (Relative Strength Index) is 42.77 on the 14-day chart, showing neutral technical sentiment.
Is Xilio Therapeutics Inc subject to short interest?
Stocks of Xilio Therapeutics Inc saw a sharp rise in short interest on 2025-05-30 jumping by 0.44 million shares to 0.79 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 0.35 million shares. A jump of 55.63% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 0.3 of the overall float, the days-to-cover ratio (short ratio) jumped to 0.3.
Which companies own the most shares of Xilio Therapeutics Inc (XLO)?
In terms of Xilio Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 7 in the next 12 months, up nearly 914.49% from the previous closing price of $0.69. Analysts anticipate Xilio Therapeutics Inc stock to reach 7 by 2025, with the lowest price target being 7. In spite of this, 1 analysts ranked Xilio Therapeutics Inc stock as Buy at the end of 2025. On November 16, 2021, Guggenheim assigned a price target of “a Buy” to the stock and initiated coverage with a $40.
